CN107095845A - A kind of antifungal ointment agent - Google Patents
A kind of antifungal ointment agent Download PDFInfo
- Publication number
- CN107095845A CN107095845A CN201710414561.XA CN201710414561A CN107095845A CN 107095845 A CN107095845 A CN 107095845A CN 201710414561 A CN201710414561 A CN 201710414561A CN 107095845 A CN107095845 A CN 107095845A
- Authority
- CN
- China
- Prior art keywords
- asiaticoside
- ointment
- group
- aucubin
- antifungal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of antifungal ointment agent of the present invention, is made up of active component and pharmaceutic adjuvant, and described active component is aucubin and Asiaticoside, and the preferably weight ratio of aucubin and Asiaticoside is 1 10：1.Medicine killing antifungal effect of the invention is more preferable, recurrence rate is low.
Description
Technical field
The invention belongs to technical field of medicine, and in particular to a kind of ointment of anti-fungal infection.
Background technology
Fungi (Fungus) is a kind of eucaryote.Most common fungi is all kinds of Mushrooms, and fungi also includes mould in addition
And yeast.More than 70,000 kinds of fungi is have now been discovered, estimation is a small half of of all presence.Most fungi was originally divided into
Animal or plant.At present, fungi has stood alone as boundary on taxology, with the animal kingdom, plant kingdom, Prokaryota and protist
Boundary is parallel.Fungi has firm cell membrane and real nucleus, is heterotrophism without chlorophyll, with parasitic or saprophytic
Mode is survived, and typical person has zoogamy and asexual reproduction concurrently, produces the spore of various forms.According to growth characteristics and poor morphology
It is different, fungi can be simply divided into yeast, fungi and gill fungus (mushroom).Wherein there is pathogenic fungi to there are about more than 300 kind to the mankind
Class.In addition to Cryptococcus neoformans and gill fungus, medically significant pathogenic fungus is nearly all mould.According to infringement human body
Difference, is clinically divided into superficial mycosis and deep fungal by pathomycete.Fungal enteritis is to belong to deep mycosis.
Superficial mycosis (tinea bacterium) only invades skin, hair and refers to (toe) first, and deep fungal can invade human body skin, stick
Film, deep tissue and internal organ, or even cause whole body disseminated infections.Deep fungal infection enteron aisle is to show as fungal enteritis,
One of it can be individually present such as baby's candida albicans enteritis, or the performance for systemic fungal infection, such as AIDS Complicated dissemination group
Knit endochylema bacterium disease.The position that fungal infectious disease invades human body according to fungi is divided into 4 classes：Superficial mycoses, dermatomycosis,
Subcutaneous mycosis and systemic mycoses；The former two is collectively referred to as superficial mycoses, and the latter two are also known as deep mycosis.Mesh
The medicine of preceding clinical treatment dermatophytid infection mainly includes imidazoles, triazole type, Allylamines broad-spectrum antifungal medicine.It is anti-true
Bacterium field still be present, such as works slow, sterilizes not thorough, high recurrence rate, protracted course of disease, many patients endure folding to the fullest extent
Mill.In addition, most of fungal infection all has itch, part is also with inflammation so that patient medication interdependence is very poor, and
Cause superinfection.Therefore, a kind of antifungal drug of better efficacy is researched and developed to be particularly important.
The content of the invention
In view of the deficiencies in the prior art, it is an object of the invention to be studied by a large amount of internal and external tests, screening is obtained
One kind killing fungi bacterium effect is more preferable, recurrence rate is low, and the pharmaceutical composition of inflammation-resisting itch-stopping, so as to provide a kind of new antimycotic
The ointment of infection.
The object of the present invention is achieved like this：
A kind of antifungal ointment agent, is made up of active component and pharmaceutic adjuvant, and described active component is aucubin
And Asiaticoside.
The weight ratio of the antifungal ointment agent, aucubin and Asiaticoside is 1-10：1.
The weight ratio of the antifungal ointment agent, aucubin and Asiaticoside is 3-5：1.
The antifungal ointment agent, ointment is made by the component of following parts by weight in it：
The antifungal ointment agent, described emulsifying agent is selected from one kind of stearic acid, single stearic acid glycerine lipoprotein and Tween 80
Or it is a variety of.
Compared with prior art, antimycotic external preparation of the present invention has the following advantages that and marked improvement：Experiment
As a result it can be seen that：Compared with model group, each administration group has to the cure rate of guinea pig skin fungal infection caused by trichophyton mentagrophytes
Certain curative effect；Compared with aucubin group and Asiaticoside group, faster, cure rate is higher for the action of compound group, shows
The unexpected antimycotic curative effect of collaboration.It is multiple compared with aucubin group and Asiaticoside group after being discontinued 3 weeks, 5 weeks
The recurrence rate of side's group is minimum, obtains unexpected technique effect.
Embodiment
Form is described in further detail again to the above of the present invention by the following examples, but should not manage this
The scope solved as above-mentioned theme of the invention is only limitted to following embodiment, and all technologies realized based on the above of the present invention are equal
Belong to the scope of the present invention.
The preparation of the compound ointment agent of embodiment 1
Ointment prescription：
Preparation technology：First stearic acid is heated in water-bath and dissolved, atoleine is added and is heated to 75 DEG C ± 2 DEG C and protects
Hold, form oil phase；Aucubin, Asiaticoside are dissolved in 1,2-PD and deionized water, Tween 80 is then added, prevents
Rotten agent, is sufficiently stirred for and is heated to 75 DEG C ± 2 DEG C and keeps, and forms aqueous phase；Finally the slow stream of oil phase is added in aqueous phase, Bian Jia
While stirring, until condensation, produces ointment.
The preparation of the compound ointment agent of embodiment 2
Ointment prescription：
Preparation technology：First single stearic acid glycerine lipoprotein is heated in water-bath and dissolved, atoleine is added and is heated to 75 DEG C
± 2 DEG C and keep, form oil phase；Aucubin, Asiaticoside are dissolved in 1,2-PD and deionized water, then added
Tween 80, preservative, are sufficiently stirred for and are heated to 75 DEG C ± 2 DEG C and keep, and form aqueous phase；The slow stream of oil phase is finally added into water
Xiang Zhong, side edged is stirred, until condensation, produces ointment.
The preparation of the compound ointment agent of embodiment 3
Ointment prescription：
Preparation technology：First single stearic acid glycerine lipoprotein is heated in water-bath and dissolved, atoleine is added and is heated to 75 DEG C
± 2 DEG C and keep, form oil phase；Aucubin, Asiaticoside are dissolved in 1,2-PD and deionized water, then added
Tween 80, preservative, are sufficiently stirred for and are heated to 75 DEG C ± 2 DEG C and keep, and form aqueous phase；The slow stream of oil phase is finally added into water
Xiang Zhong, side edged is stirred, until condensation, produces ointment.
Comparative example 1
Ointment prescription：The preparation of aucubin ointment
Preparation technology：Be the same as Example 1.
The preparation of the Asiaticoside ointment of comparative example 2
Ointment prescription：
Preparation technology：Be the same as Example 1.
The preparation of the blank ointment of comparative example 3
Ointment prescription：
Preparation technology：Be the same as Example 1.
Embodiment 4：Influence of the ointment of the present invention to guinea pig skin infection model caused by trichophyton mentagrophytes
It is made after trichophyton mentagrophytes is inoculated in into husky fort agar (SDA) slant tube, 26 DEG C of cultures, 7-10d of physiological saline
Suspension is standby, husky fort agar by 1% peptone and 2% glucose group into.
Healthy guinea pig, male and female half and half, body weight (250 ± 10) g.All guinea pig back shavings, shaving area 6cm at one2
Shaving area at (2cm*3cm), every cavy two.Wiped with fine sandpaper (400#) at shaving position.Then sterile saline is used
After cleaning 3 times, ready trichophyton mentagrophytes is dipped with cotton swab and is coated on wound site.Bacterium solution is coated with continuous 10 days, and 2 times a day.
After clean wound site on the 11st, the scales of skin that peel off at position carries out microscopy observation at random picking 3.According to the feature of skin damaged and direct mirror
The bacterial strain of detection, judges the foundation of infection model.The furfur of animal, hair, crust turn out corresponding fungi after infection, through true
Bacterium microscopy is the positive, model success.
The infection successful cavy 48 of trichophyton mentagrophytes is taken, following each group is randomly divided into：Model control group (comparative example 3
The ointment of preparation), aucubin group (comparative example 1 prepare ointment), Asiaticoside group (make by comparative example 2
Standby ointment), compound group (embodiment 1 prepare ointment), every group 12, male and female half and half.Corresponding medicine is taken by table 1
Cavy cutaneous lesion is wiped, continuous use 14 days twice daily, is spaced 12h.
Since inoculation the 2nd day, taken every 3 days and the scales of skin that peel off is taken around above-mentioned experiment cavy diseased region, every animal takes 3
Place, microscopy after being digested with potassium hydroxide, it is the positive to have mycelia person, is otherwise feminine gender.
Cure and disappear for skin damaged, fungus microscope examination is double for feminine gender；Invalid not disappeared for skin damaged, fungus microscope examination is in sun
Property；Do not disappeared for skin damaged effectively, fungus microscope examination is feminine gender.Calculate every group of cure rate=(curing sample number/microscopy total sample number)
× 100%.
Continuous use is discontinued medication after 2 weeks, normal to feed, week about fungus microscope examination, and fungus microscope examination shows for positive
Recurrence, records recurrence number every time.Calculate end-of-dose failure rate=recurrence number/inspection total sample number × 100%.
Influence of each group medicine of table 1 to guinea pig skin infection model cure rate caused by trichophyton mentagrophytes
Recurrence of each group medicine of table 2 to guinea pig skin infection model caused by trichophyton mentagrophytes
It can be seen that according to the result of the test of table 1, table 2：Compared with model group, each administration group is to cavy caused by trichophyton mentagrophytes
The cure rate of dermatophytid infection has certain curative effect；Compared with aucubin group and Asiaticoside group, of compound group
Faster, cure rate is higher, shows the antimycotic curative effect of unexpected collaboration for effect.In addition, after being discontinued 3 weeks, 5 weeks, with peach
Leaf coral glycosides group is compared with Asiaticoside group, and the recurrence rate of compound group is minimum, obtains unexpected technique effect.
Claims (5)
1. a kind of antifungal ointment agent, is made up of active component and pharmaceutic adjuvant, it is characterised in that：Described active component is peach
Leaf coral glycosides and Asiaticoside.
2. antifungal ointment agent according to claim 1, it is characterised in that：The weight ratio of aucubin and Asiaticoside is
1-10：1.
3. antifungal ointment agent according to claim 1, it is characterised in that：The weight ratio of aucubin and Asiaticoside is
3-5：1.
4. antifungal ointment agent according to claim 1 or claim 2, it is characterised in that：It is made up soft of the component of following parts by weight
Paste：
5. antifungal ointment agent according to claim 4, it is characterised in that：Described emulsifying agent is selected from stearic acid, single tristearin
The one or more of acid glyceride and Tween 80.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710414561.XA CN107095845A (en) | 2017-06-05 | 2017-06-05 | A kind of antifungal ointment agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710414561.XA CN107095845A (en) | 2017-06-05 | 2017-06-05 | A kind of antifungal ointment agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107095845A true CN107095845A (en) | 2017-08-29 |
Family
ID=59661007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710414561.XA Withdrawn CN107095845A (en) | 2017-06-05 | 2017-06-05 | A kind of antifungal ointment agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107095845A (en) |
-
2017
- 2017-06-05 CN CN201710414561.XA patent/CN107095845A/en not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| 王筱婧等: "积雪草苷对阿尔茨海默病的治疗作用", 《中国医药科学》 * |
| 薛宏宇等: "桃叶珊瑚苷提取及对细胞氧化损伤保护作用", 《光谱实验室》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10238665B2 (en) | Methods for treating fungal infections | |
| CN102985091B (en) | Use antimicrobial peptide chelate compound treatment dermatosis and abnormal compositions and method | |
| US20190142800A1 (en) | Synergistic antifungal compositions and methods thereof | |
| WO2017216722A2 (en) | Synergistic antifungal compositions and methods thereof | |
| CN102065851A (en) | Nanoemulsions for treating fungal, yeast and mold infections | |
| CN107249584A (en) | Composition and method for suppressing fungal infection | |
| CN104146957A (en) | Submicroemulsion antifungal drug spray preparation | |
| Sánchez et al. | Use of propolis for topical treatment of dermatophytosis in dog | |
| CN100998575A (en) | Finger nail coating agent of antifungal agent and its preparing method | |
| CN103622955B (en) | Ellagic acid is being treated and is being prevented the application in the medicine of Human Fungi infection | |
| CN116211766A (en) | Black tea fermentation product and application thereof | |
| CN102048731B (en) | Externally applied pharmaceutical composition for treating skin fungal infection | |
| US10617659B2 (en) | Valproate as a topical anti-fungal treatment | |
| CN107095845A (en) | A kind of antifungal ointment agent | |
| CN105362257B (en) | A kind of traditional Chinese medicine extraction composition being used to prepare anti-dermatophyte infection medicine | |
| US20110118220A1 (en) | Composition of bifonazole and its use | |
| CN109453116A (en) | A kind of terbinafine HCl spray and preparation method thereof | |
| CN103251636A (en) | Medicament for treating Candida infections and diseases caused by Candida, and preparation method thereof | |
| CN106309473A (en) | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof | |
| US11779553B1 (en) | Methods and devices for treatment of eyelid ptosis | |
| EP1397124B1 (en) | Use of antidiabetics for making a medicine with cicatrizing effect | |
| CN111228260B (en) | Composition containing rapamycin and application thereof | |
| Amorim et al. | Coccidioidomycosis in a cat imported from the USA to Portugal | |
| CN102526051A (en) | Eye ointment for treating fungal keratitis | |
| CN114010790B (en) | Use of fluorescent whitening agents against fungal infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170829 |